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Cancer is one of the leading causes of morbidity and mor-
tality in the world, and the global burden of cancer is pre-
dicted to grow rapidly in the coming decade. While cancer 
affects all communities indiscriminately, there are striking 
differences in the incidence and mortality among differ-
ent populations. These large differences reflect a combina-
tion of differences in the prevalence of risk factors, differ-
ences in genetic susceptibility, and/or variations in cancer 
detection, reporting, classification systems, treatment, and 
follow-up. Unfortunately, developing nations or nations in 
the so called economical transition are those with the fast-
est growing cancer problem. The International Agency for 
Research on Cancer estimated that over a half of newly di-
agnosed cases and two-thirds of cancer deaths occur in 
low and medium-income countries (1). Priority setting for 
cancer control and cancer services in any region needs to 
be based on knowledge of the cancer burden and of the 
local mix of predominant cancer types (2).
There are striking variations in the regional cancer patterns. 
Among European countries, wide differences are observed 
in the quality of cancer care, especially between developed 
and low-resource, transitional countries (3). In general, can-
cer survival is significantly lower in transitional European 
countries than in the developed ones (3).
In order to appropriately allocate financial and other re-
sources in the fight against cancer it is essential to have ep-
idemiological information, plan treatment strategies, and 
address access issues. An important first step that could 
provide a basis on which to plan future epidemiology proj-
ects and ultimately to improve the quality of cancer care in 
Croatia is gaining accurate knowledge on the cancer reg-
istry data in Croatia.
This issue of the Croatian Medical Journal (CMJ) publishes 
six articles by different groups of authors led by Dr Ariana 
Znaor  from  Croatian  National  Institute  of  Public  Health 
(4-9). They analyzed melanoma, lung, colon, gastric, breast, 
uterine,  ovarian,  cervical,  prostate  cancer,  and  leukemia 
and lymphoma incidence and mortality trends in Croatia 
from 1988 till 2008, and compared them with the trends 
in other, especially European populations. Their epidemio-
logical analysis indicates the scale of the problem of onco-
logical care in Croatia. Also, the comparison of the oncol-
ogy status between Croatia and other countries is of great 
importance since the key barriers to delivery of appropri-
ate quality of cancer care within limited resources environ-
ment have not been previously identified. Unfortunately, 
incidence and mortality trends for most of investigated 
cancer sites were less favorable than in Western European 
countries (10,11). In particular, Croatia has one of the high-
est rates in Europe for lung cancer and other tobacco-re-
lated cancers (5). Of course, it is well known that to have fa-
vorable trends in cancer mortality, societies would require 
a strategy focusing on the control of tobacco and alcohol 
consumption, adequate nutrition, and avoidance of exces-
sive sun exposure (12). Early diagnosis can also have a rele-
vant impact, and this together with the universal adoption 
of recent therapeutic advances and better organization of 
oncology system in general (adherence to guidelines, re-
ferral centers with multidisciplinary team work, optimal ac-
cess to treatment, especially targeted drugs), may contrib-
ute to reducing the cancer mortality burden (10,12).
The most important factors that influence cancer mortal-
ity rates are adequate cancer prevention, screening, diag-
nosis, and treatment (10). Also, the distribution of differ-
ent types of cancer is equally important. Namely, while in 
developed countries the most common type of cancer in 
men is prostate cancer, in the developing world and Croa-
tia the most prevalent cancer is lung cancer, a significant-
ly more dangerous tumor type. The excess mortality from 
these neoplasms in Croatia and other transitional countries 
could therefore be reduced if adequate resources, training, 
and logistics to deliver adequate preventive measures, di-
agnosis, and treatment were implemented.
In the articles published in this issue of the CMJ, the inci-
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al Cancer Registry and the mortality data from the Croatian 
Bureau of Statistics or from the World Health Organization 
mortality database. In addition to incidence and mortality 
data collected by cancer registries, data related to underly-
ing risk factors and treatment of patients should become 
more available, leading to more important and valuable in-
formation from a health outcomes point of view.
In conclusion, new and comprehensive data about selec-
tive cancer incidence and mortality in Croatia highlight the 
importance of the subject and the need to invest more in 
all known activities related to the fight against cancer – ed-
ucation, prevention, early detection, better access to ad-
equate anticancer treatments, and multidisciplinary work.
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